Vera Therapeutics (NASDAQ:VERA) CEO Sells $649,720.00 in Stock

by · The Markets Daily

Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) CEO Marshall Fordyce sold 18,500 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $35.12, for a total transaction of $649,720.00. Following the sale, the chief executive officer owned 235,244 shares of the company’s stock, valued at approximately $8,261,769.28. The trade was a 7.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Marshall Fordyce also recently made the following trade(s):

  • On Tuesday, July 7th, Marshall Fordyce sold 46,250 shares of Vera Therapeutics stock. The shares were sold at an average price of $42.30, for a total transaction of $1,956,375.00.
  • On Tuesday, June 23rd, Marshall Fordyce sold 18,500 shares of Vera Therapeutics stock. The stock was sold at an average price of $37.93, for a total value of $701,705.00.

Vera Therapeutics Trading Up 2.6%

Shares of NASDAQ VERA traded up $0.90 during mid-day trading on Friday, reaching $35.89. 1,184,368 shares of the company’s stock were exchanged, compared to its average volume of 1,505,769. The firm has a market capitalization of $2.59 billion, a price-to-earnings ratio of -6.12 and a beta of 0.96. Vera Therapeutics, Inc. has a 52-week low of $21.96 and a 52-week high of $56.05. The company’s 50-day moving average is $35.99 and its 200-day moving average is $37.47. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.92 and a current ratio of 10.92.

Vera Therapeutics (NASDAQ:VERA – Get Free Report) last issued its quarterly earnings data on Monday, August 10th. The company reported ($1.52) EPS for the quarter, topping the consensus estimate of ($1.58) by $0.06. During the same quarter last year, the business earned ($1.20) earnings per share. Analysts expect that Vera Therapeutics, Inc. will post -6.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

VERA has been the topic of a number of recent research reports. Bank of America upped their price objective on Vera Therapeutics from $65.00 to $70.00 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. HC Wainwright decreased their price objective on Vera Therapeutics from $125.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday, August 12th. William Blair restated an “outperform” rating on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Raymond James Financial reiterated a “strong-buy” rating and set a $84.00 price target on shares of Vera Therapeutics in a report on Tuesday, August 11th. Finally, Guggenheim lifted their price objective on shares of Vera Therapeutics from $56.00 to $76.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $81.15.

View Our Latest Report on Vera Therapeutics

Hedge Funds Weigh In On Vera Therapeutics

Hedge funds have recently made changes to their positions in the company. California State Teachers Retirement System lifted its position in Vera Therapeutics by 4,071.9% during the 2nd quarter. California State Teachers Retirement System now owns 2,074,999 shares of the company’s stock worth $89,038,000 after acquiring an additional 2,025,262 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in shares of Vera Therapeutics by 49.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,461,976 shares of the company’s stock valued at $276,595,000 after buying an additional 1,795,537 shares in the last quarter. Vestal Point Capital LP raised its position in Vera Therapeutics by 24.0% in the second quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company’s stock worth $73,036,000 after acquiring an additional 600,000 shares in the last quarter. Elmind Capital LP purchased a new stake in shares of Vera Therapeutics during the 4th quarter worth $24,434,000. Finally, Armistice Capital LLC grew its stake in shares of Vera Therapeutics by 294.1% during the 3rd quarter. Armistice Capital LLC now owns 536,000 shares of the company’s stock worth $15,576,000 after purchasing an additional 400,000 shares during the period. Hedge funds and other institutional investors own 99.21% of the company’s stock.

About Vera Therapeutics

(Get Free Report)

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.

Featured Stories